COVID-19: A Healthcare Stakeholders Analysis in the United States and EU-5

COVID-19: Monitoring Impacts and Anticipating Trends to Limit Downturn and Optimize Rebound

Publications
Published on:
April 14, 2020
A Healthcare Stakeholders Analysis in the United States and EU-5 and a Practical Guide for Product Suppliers

The COVID-19 pandemic is having a disruptive effect on every corner of the healthcare industry, but its impact on individual stakeholders varies widely. Differences in exposure to COVID-19 patients, the relevance of product portfolios to the disease, and the level of preparedness for a pandemic have forced many across the industry to re-evaluate their strategies, quickly pivot to support urgent needs, and work to strengthen their position for the long-term rebound.

Alira Health’s team of strategists, scientists, doctors, and bankers continue to monitor the key trends and will share their perspective on underlying short, medium and long term implications to support the industry through this crisis and help continue to move healthcare forward during this time of uncertainty.

This 20-page report includes comprehensive analyses of the COVID-19 impact as of April 14, including:
  • An up-to-date digest of the impact COVID-19 is having on key healthcare stakeholders
  • Analysis of key trends and anticipated emerging needs
  • Business approaches for short-term reaction, and business model adaptations to help optimize for the rebound

 

For more information please contact our team:

Take our COVID-19 Impact Survey

Get started

 

Alira Health makes no representations or warranties, either expressed or implied, as to the accuracy of the information in this report. Alira Health has collected and compiled the presented information on a best effort basis under time and budget constraints. In no event will Alira Health be held liable for any direct, indirect, incidental or consequential damages arising out of the use of the information in this report.

Unless otherwise explicitly stated, all information is copyrighted by Alira Health, irrespective of whether a copyright symbol and statement is present. All trademarks are acknowledged.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Publications July 14, 2022
How to successfully use the EMA IRIS portal to ensure timely submissions
Submitting your scientific advice (SA), orphan drug designation (ODD) or Innovation Task Force (ITF) consultation to the EMA? Avoid delays with our submission recommendations.
European Medicines Agency Orphan Drug Regulatory
Multimedia July 12, 2022
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
MedTech Regulatory
Events June 30, 2022
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
DTx trends Market Access Regulatory
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.